What is Zacks Research’s Forecast for ENSC Q1 Earnings?

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Research analysts at Zacks Research issued their Q1 2026 earnings per share (EPS) estimates for shares of Ensysce Biosciences in a research note issued to investors on Tuesday, March 31st. Zacks Research analyst B. Sorensen expects that the company will post earnings of ($0.73) per share for the quarter. The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($8.33) per share. Zacks Research also issued estimates for Ensysce Biosciences’ Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.67) EPS and FY2026 earnings at ($3.54) EPS.

Ensysce Biosciences (NASDAQ:ENSC) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.51. Ensysce Biosciences had a negative return on equity of 458.65% and a negative net margin of 200.87%.The business had revenue of $1.88 million for the quarter, compared to analyst estimates of $0.50 million.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Ensysce Biosciences Stock Up 11.4%

Shares of NASDAQ:ENSC opened at $0.61 on Thursday. Ensysce Biosciences has a twelve month low of $0.31 and a twelve month high of $4.85. The stock’s 50 day moving average is $0.54 and its 200-day moving average is $1.32. The firm has a market capitalization of $2.21 million, a price-to-earnings ratio of -0.14 and a beta of 1.12.

Institutional Trading of Ensysce Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENSC. TRU Independence Asset Management 2 LLC bought a new position in shares of Ensysce Biosciences in the third quarter valued at approximately $25,000. Citadel Advisors LLC purchased a new position in shares of Ensysce Biosciences during the third quarter valued at approximately $34,000. Virtu Financial LLC bought a new stake in Ensysce Biosciences during the third quarter worth $34,000. DRW Securities LLC raised its position in Ensysce Biosciences by 42.4% in the 4th quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after buying an additional 29,336 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its position in Ensysce Biosciences by 100.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after buying an additional 75,000 shares during the last quarter. 5.63% of the stock is owned by institutional investors.

About Ensysce Biosciences

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.